Sugi Predict

Sugi Predict / Targets / F12

F12

Coagulation factor XII · P00748 · F12 on Sugi Atlas →

24,440 patent compounds predicted against F12, 15,147 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL768982 SCHEMBL768982 0.46 16/20
SCHEMBL618825 SCHEMBL618825 0.45 12/20
SCHEMBL830434 SCHEMBL830434 0.47 8/20
SCHEMBL459733 SCHEMBL459733 0.60 7/20
Nafamostat Nafamostat (SCHEMBL874941) 0.58 7/20
SCHEMBL443991 SCHEMBL443991 0.57 7/20
SCHEMBL535054 SCHEMBL535054 0.57 7/20
SCHEMBL535509 SCHEMBL535509 0.53 7/20
SCHEMBL861206 SCHEMBL861206 0.53 7/20
SCHEMBL570956 SCHEMBL570956 0.49 7/20
Nafamostat Nafamostat (SCHEMBL135503) 0.64 6/20
SCHEMBL427058 SCHEMBL427058 0.61 6/20
SCHEMBL170673 SCHEMBL170673 0.58 6/20
Nafamostat Nafamostat (SCHEMBL564665) 0.58 6/20
SCHEMBL425777 SCHEMBL425777 0.55 6/20
SCHEMBL425007 SCHEMBL425007 0.53 6/20
SCHEMBL427308 SCHEMBL427308 0.47 6/20
SCHEMBL711731 SCHEMBL711731 0.44 6/20
SCHEMBL424354 SCHEMBL424354 0.44 6/20
Sepimostat Sepimostat (SCHEMBL872319) 1.00 5/20

Clinical trials — most relevant to F12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor PHASE4RECRUITING
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal PHASE4COMPLETED
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock PHASE2/PHASE3COMPLETED
A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years PHASE3COMPLETED
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. PHASE3COMPLETED
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A PHASE3ACTIVE_NOT_RECRUITING
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE3COMPLETED
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A PHASE3COMPLETED
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A PHASE3COMPLETED
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B PHASE2COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System PHASE1COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome PHASE1COMPLETED
Correlation Between PT and INR to Factor 7 nanUNKNOWN
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects nanUNKNOWN
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia nanCOMPLETED
Coagulation After Intravenous Methylprednisolone Administration nanCOMPLETED
Risk Factors of Neonatal Thrombosis nanCOMPLETED
Heparin Management During Cardiopulmonary Bypass in Children nanCOMPLETED
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital nanUNKNOWN
Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010 nanUNKNOWN
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer nanUNKNOWN
Rare Bleeding Disorders in the Netherlands nanUNKNOWN
Common Variants in Candidate Genes and Premature MI Risk nanCOMPLETED
Effects of the Bone Tissue on the Haemostasis nanUNKNOWN
Pattern of Menorrhagic Female Attending the Hematology Unit in Assuit University Children Hospital nanNOT_YET_RECRUITING
Comparison of Factor XII Levels in Gestational Diabetic and Healthy Pregnancies nanCOMPLETED
Risk Markers in the Acute Coronary Syndromes nanCOMPLETED
The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation nanCOMPLETED
Mechanism and Repository Study for the Red Cell Storage Duration Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a F12 binder may also engage these)

ProteinNameSimilarity
O97507 — 1.000 O97507 →
Q80YC5 — 1.000 Q80YC5 →
D3ZTE0 — 1.000 D3ZTE0 →
P98140 — 1.000 P98140 →
Q04962 — 0.999 Q04962 →
HGFAC Hepatocyte growth factor activator serine protease 0.994 landscape →
Q6QNF4 — 0.992 Q6QNF4 →
F7 Coagulation factor VII 0.991 landscape →
Q2F9P2 — 0.990 Q2F9P2 →
Q9R098 — 0.990 Q9R098 →
TMPRSS6 Transmembrane protease serine 6 0.989 landscape →
P22457 — 0.987 P22457 →
Q24K22 — 0.987 Q24K22 →
P69526 — 0.987 P69526 →
P00744 — 0.986 P00744 →
MST1 Hepatocyte growth factor-like protein 0.986 landscape →
P00743 — 0.986 P00743 →
ADAMTS13 A disintegrin and metalloproteinase with thrombospondin motifs 13 0.986 landscape →
Q9H3S3 — 0.985 Q9H3S3 →
Q3UZ09 — 0.985 Q3UZ09 →
Q9BY79 — 0.985 Q9BY79 →
O95428 — 0.985 O95428 →
PROC Vitamin K-dependent protein C 0.985 landscape →
P22891 — 0.985 P22891 →
Q9NPY3 — 0.985 Q9NPY3 →
Q2F9P4 — 0.984 Q2F9P4 →
P69525 — 0.984 P69525 →
Q6ZRI0 — 0.984 Q6ZRI0 →
Q9ER04 — 0.984 Q9ER04 →
Q7Z410 — 0.984 Q7Z410 →